diabetes

Health tech Mario Aguilar

STAT Plus: Health tech investor Glen Tullman launches 62 Ventures, a new $100 million fund

Biotech Elaine Chen

STAT Plus: Parkinson’s disease may be helped by GLP-1 drug, new study finds

Health Annalisa Merelli

STAT Plus: GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable

Health Elaine Chen

Ozempic-like drugs linked to low, but increased risk of post-endoscopy pneumonia, study finds

Health tech Katie Palmer and Mario Aguilar

STAT Plus: Digital tools for diabetes management did not deliver benefits that justify cost, new report finds

Health tech Katie Palmer and Lizzy Lawrence

STAT Plus: FDA clears first over-the-counter continuous glucose monitor

Health Elaine Chen

STAT Plus: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound

Health Elaine Chen

STAT Plus: Can Wegovy treat depression as well as obesity? New research looks to GLP-1 drugs for mental illnesses

Health Elaine Chen

GLP-1 drugs not linked to suicidal thoughts in FDA’s early review

Biotech Adam Feuerstein

STAT Plus: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study

Politics John Wilkerson

STAT Plus: Sanders blames food companies for diabetes epidemic

Health tech Lizzy Lawrence

STAT Plus: Medtronic cancels $738 million acquisition of diabetes tech company EOFlow

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Diabetes ‘epidemic’ gets a Senate hearing

Pharmalot Ed Silverman and John Wilkerson

STAT Plus: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs

Biotech Annalisa Merelli

STAT Plus: What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today

Health Andrew Joseph

Type 2 diabetes prevention programs can work at large scale, study finds

Health Anika Nayak

Fresh produce access boosts health outcomes among diabetes patients and those on Medicaid in recent studies

Pharma Elaine Chen

STAT Plus: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation

Health tech Katie Palmer

STAT Plus: Patients loved Carbon Health’s diabetes program. That couldn’t save it

D.C. Diagnosis Rachel Cohrs Zhang

Medicare eligibility is tripping up the GOP presidential candidates

Politics Sarah Owermohle

STAT Plus: Senator floats new models to manage costs of weight loss drugs like Ozempic

Pharma Elaine Chen and Damian Garde

STAT Plus: Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound

Health Katherine MacPhail

Why preventative care is such a tough sell in the U.S., according to chronic disease experts

First Opinion David Panzirer

Insulin is increasingly affordable in the U.S. What about the rest of the world?

The Obesity Revolution Megan Molteni

STAT Plus: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse

Health tech Mario Aguilar

STAT Plus: Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag

Health Nicholas St. Fleur

‘What I’m most proud of’: Nick Jonas talks about managing diabetes, his career, and building community

The Obesity Revolution Megan Molteni and Elaine Chen

GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?

The Obesity Revolution Elaine Chen and Megan Molteni

STAT Plus: The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the story